Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17542899rdf:typepubmed:Citationlld:pubmed
pubmed-article:17542899lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17542899lifeskim:mentionsumls-concept:C0231335lld:lifeskim
pubmed-article:17542899lifeskim:mentionsumls-concept:C0027342lld:lifeskim
pubmed-article:17542899lifeskim:mentionsumls-concept:C0033860lld:lifeskim
pubmed-article:17542899lifeskim:mentionsumls-concept:C0288792lld:lifeskim
pubmed-article:17542899pubmed:issue3lld:pubmed
pubmed-article:17542899pubmed:dateCreated2007-6-4lld:pubmed
pubmed-article:17542899pubmed:abstractTextNail psoriasis occurs in 7% to 40% of children, with a similar pattern of clinical presentation to that of adults. In 0.6% to 2.3% of the patients nail changes appear as the only sign of the disease, preceding other skin and articular involvement. No pediatric clinical trials are available yet, but considering the successful use of tazarotene for nail dystrophy therapy in adults, we chose this drug to treat a child.lld:pubmed
pubmed-article:17542899pubmed:languageenglld:pubmed
pubmed-article:17542899pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17542899pubmed:citationSubsetIMlld:pubmed
pubmed-article:17542899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17542899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17542899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17542899pubmed:statusMEDLINElld:pubmed
pubmed-article:17542899pubmed:issn0736-8046lld:pubmed
pubmed-article:17542899pubmed:authorpubmed-author:ChimentiSergi...lld:pubmed
pubmed-article:17542899pubmed:authorpubmed-author:MordentiCrist...lld:pubmed
pubmed-article:17542899pubmed:authorpubmed-author:CampioneElena...lld:pubmed
pubmed-article:17542899pubmed:authorpubmed-author:El...lld:pubmed
pubmed-article:17542899pubmed:authorpubmed-author:DiluvioLauraLlld:pubmed
pubmed-article:17542899pubmed:authorpubmed-author:PaternòEvelin...lld:pubmed
pubmed-article:17542899pubmed:issnTypePrintlld:pubmed
pubmed-article:17542899pubmed:volume24lld:pubmed
pubmed-article:17542899pubmed:ownerNLMlld:pubmed
pubmed-article:17542899pubmed:authorsCompleteYlld:pubmed
pubmed-article:17542899pubmed:pagination332-3lld:pubmed
pubmed-article:17542899pubmed:dateRevised2009-3-3lld:pubmed
pubmed-article:17542899pubmed:meshHeadingpubmed-meshheading:17542899...lld:pubmed
pubmed-article:17542899pubmed:meshHeadingpubmed-meshheading:17542899...lld:pubmed
pubmed-article:17542899pubmed:meshHeadingpubmed-meshheading:17542899...lld:pubmed
pubmed-article:17542899pubmed:meshHeadingpubmed-meshheading:17542899...lld:pubmed
pubmed-article:17542899pubmed:meshHeadingpubmed-meshheading:17542899...lld:pubmed
pubmed-article:17542899pubmed:meshHeadingpubmed-meshheading:17542899...lld:pubmed
pubmed-article:17542899pubmed:meshHeadingpubmed-meshheading:17542899...lld:pubmed
pubmed-article:17542899pubmed:articleTitleChildhood nail psoriasis: a useful treatment with tazarotene 0.05%.lld:pubmed
pubmed-article:17542899pubmed:affiliationDepartment of Dermatology, University of Rome Tor Vergata, Rome, Italy. lauradiluvio@yahoo.itlld:pubmed
pubmed-article:17542899pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17542899pubmed:publicationTypeCase Reportslld:pubmed